B-cell malignancy lymph node cancer
Conditions
Interventions
all patients will receive the pneumococcal conjugate vaccine Prevnar®, the Hib
conjugate vaccine Act-Hib®, the influenza virus vaccine Influvac® and the
pneumococcal polysaccharide vaccine Pneumovax
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patients with non-Hodgkin's lymphoma, treated with rituximab (approximately 6-8 cycles) and who are in remission. - Completion of rituximab therapy in the last twelve months before start of the study - Age 18 years or older - Signing of informed consent
Exclusion criteria
Exclusion criteria: - Vaccination with Hib or pneumococcal vaccine in the last fifteen months before start of the study - Fever at time of vaccination - Previous/known allergic reaction to any of the components of the vaccines given
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody titres against S. pneumoniae and H. influenzae type b (in µg/mL) and the influenza virus before and after vaccination. The association between the reconstitution of immune function after treatment with rituximab (in terms of amount of B-cells and immunoglobulin levels) and the rise in antibody titre. | — |
Secondary
| Measure | Time frame |
|---|---|
| o The effect of the use of growth factor during chemotherapy on the response to vaccination o The relationship between time since last rituximab-dose and the rise in antibody titre | — |
Countries
Netherlands
Outcome results
None listed